Cognition Therapeutics (CGTX) to Release Earnings on Wednesday

Cognition Therapeutics (NASDAQ:CGTX) is expected to release its Q3 2025 results before the market opens on Wednesday, November 12th. Analysts expect the company to announce earnings of ($0.07) per share for the quarter. Parties can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Friday, November 14, 2025 at 4:00 PM ET.

Cognition Therapeutics (NASDAQ:CGTX) last issued its earnings results on Thursday, August 7th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.01. On average, analysts expect Cognition Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cognition Therapeutics Trading Down 4.3%

CGTX opened at $1.57 on Wednesday. The company’s fifty day moving average price is $1.84 and its two-hundred day moving average price is $1.05. Cognition Therapeutics has a 1-year low of $0.22 and a 1-year high of $3.83. The company has a market cap of $115.43 million, a price-to-earnings ratio of -2.34 and a beta of 1.23.

Hedge Funds Weigh In On Cognition Therapeutics

A hedge fund recently raised its stake in Cognition Therapeutics stock. Acadian Asset Management LLC grew its position in shares of Cognition Therapeutics, Inc. (NASDAQ:CGTX) by 814.1% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,007,586 shares of the company’s stock after buying an additional 897,353 shares during the quarter. Acadian Asset Management LLC owned 1.63% of Cognition Therapeutics worth $422,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 43.35% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on CGTX shares. Chardan Capital restated a “buy” rating and issued a $4.00 target price on shares of Cognition Therapeutics in a report on Friday, August 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Cognition Therapeutics in a research note on Wednesday, October 8th. Finally, Wall Street Zen downgraded Cognition Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, September 26th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $2.83.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.